{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:00:45Z","timestamp":1780923645464,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus Dresden an der Technischen Universit\u00e4t Dresden"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>For younger, medically fit patients with <jats:italic>NPM1<\/jats:italic>-mutated, <jats:italic>FLT3<\/jats:italic>-wildtype acute myeloid leukemia (AML) intensive chemotherapy represents standard of care (SOC), with complete remission (CR) rates observed in up to 85% of patients and 5-year overall survival (OS) rates of 40\u201350%. However, significant toxicity and need for hospitalization pose challenges on patients\u2019 outcome and quality of life (QoL). Venetoclax (VEN) combined with azacitidine (AZA) has demonstrated encouraging efficacy in older, unfit AML patients, achieving high CR\/CRi rates and promising OS with lower toxicity. Prospective, randomized data comparing VEN\/AZA to SOC in younger, fit patients are currently missing. VINCENT is a randomized-controlled, multicenter, non-inferiority, phase 2 trial (NCT05904106) evaluating VEN\/AZA versus SOC in adults aged 18\u201370 years with newly diagnosed, <jats:italic>NPM1<\/jats:italic>-mutated, <jats:italic>FLT3<\/jats:italic>-wildtype AML. Patients medically fit for intensive chemotherapy (ECOG\u2009\u2264\u20092) with adequate organ function are eligible, while patients with relapsed\/refractory AML or prior cytotoxic treatment are excluded. A total of 146 patients will be randomized 1:1 to receive either VEN\/AZA or SOC. Hematologic remission is evaluated according to ELN 2022 guidelines. The primary endpoint is the modified event-free survival, defined as either primary induction failure, hematologic relapse, molecular failure or death. Secondary endpoints include safety, tolerability, CR\/CRi\/CRh\/CR<jats:sub>MRD\u2212<\/jats:sub> rates, MRD kinetics (using <jats:italic>NPM1<\/jats:italic> RT-qPCR and MFC), relapse-free survival, OS, early mortality, health-related QoL and cumulative health-care-resource use. Patients will be followed up for at least two years post enrollment. The VINCENT trial will be the first study to provide comprehensive prospective data comparing VEN\/AZA to SOC, addressing both efficacy and patient-centered outcomes.<\/jats:p>","DOI":"10.1007\/s00277-025-06496-7","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:26:13Z","timestamp":1752139573000},"page":"3647-3654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML"],"prefix":"10.1007","volume":"104","author":[{"given":"Lydia","family":"Kretschmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Ruhnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schliemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Fransecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Burchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Hanoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus H.","family":"Metzeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Sch\u00e4fer-Eckart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Crysandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan W.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Dierks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas P.","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veit L.","family":"B\u00fccklein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wegehenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"H\u00f6llein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Seggewiss-Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenke","family":"Markgraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Fiebig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Harig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Schmidt-Br\u00fccken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thiede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Moritz","family":"Middeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia D.","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Spiekermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Schlenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"6496_CR1","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1182\/BLOOD.2019004226","volume":"136","author":"B Falini","year":"2020","unstructured":"Falini B, Brunetti L, Sportoletti P, Paola Martelli M (2020) NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood 136:1707\u20131721. https:\/\/doi.org\/10.1182\/BLOOD.2019004226","journal-title":"Blood"},{"key":"6496_CR2","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1182\/BLOOD-2005-04-1733","volume":"106","author":"T Suzuki","year":"2005","unstructured":"Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda R, Kinoshita T, Emi N, Naoe T (2005) Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 106:2854\u20132861. https:\/\/doi.org\/10.1182\/BLOOD-2005-04-1733","journal-title":"Blood"},{"key":"6496_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/BLOOD.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, R\u00f6llig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, L\u00f6wenberg B (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377. https:\/\/doi.org\/10.1182\/BLOOD.2022016867","journal-title":"Blood"},{"key":"6496_CR4","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1200\/JCO.19.00416","volume":"37","author":"L Angenendt","year":"2019","unstructured":"Angenendt L, R\u00f6llig C, Montesinos P, Mart\u00ednez-Cuadr\u00f3n D, Barragan E, Garc\u00eda R, Botella C, Mart\u00ednez P, Ravandi F, Kadia T, Kantarjian HM, Cortes J, Juliusson G, Lazarevic V, H\u00f6glund M, Lehmann S, Recher C, Pigneux A, Bertoli S, Dumas PY, Dombret H, Preudhomme C, Micol JB, Terr\u00e9 C, R\u00e1\u010dil Z, Nov\u00e1k J, \u017d\u00e1k P, Wei AH, Tiong IS, Wall M, Estey E, Shaw C, Exeler R, Wagenf\u00fchr L, St\u00f6lzel F, Thiede C, Stelljes M, Lenz G, Mikesch JH, Serve H, Ehninger G, Berdel WE, Kramer M, Krug U, Schliemann C (2019) Chromosomal abnormalities and prognosis in NPM1-Mutated acute myeloid leukemia: A pooled analysis of individual patient data from nine international cohorts. J Clin Oncol 37:2632\u20132642. https:\/\/doi.org\/10.1200\/JCO.19.00416","journal-title":"J Clin Oncol"},{"key":"6496_CR5","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/S2352-3026(23)00089-3","volume":"10","author":"H D\u00f6hner","year":"2023","unstructured":"D\u00f6hner H, Weber D, Krzykalla J, Fiedler W, K\u00fchn MWM, Schroeder T, Mayer K, L\u00fcbbert M, Wattad M, G\u00f6tze K, Fransecky L, Koller E, Wulf G, Schleicher J, Ringhoffer M, Greil R, Hertenstein B, Krauter J, Martens UM, Nachbaur D, Samra MA, Machherndl-Spandl S, Basara N, Leis C, Schrade A, Kapp-Schwoerer S, Cocciardi S, Bullinger L, Thol F, Heuser M, Paschka P, Gaidzik VI, Saadati M, Benner A, Schlenk RF, D\u00f6hner K, Ganser A, K\u00fchn MWM, Wattad M, Martens UM, Gaidzik VI, Schlenk RF (2023) Intensive chemotherapy with or without Gemtuzumab Ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09\u201309): a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol 10:e495\u2013e509. https:\/\/doi.org\/10.1016\/S2352-3026(23)00089-3","journal-title":"Lancet Haematol"},{"key":"6496_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/S10557-016-6711-0","volume":"31","author":"JV McGowan","year":"2017","unstructured":"McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM (2017) Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 31:63. https:\/\/doi.org\/10.1007\/S10557-016-6711-0","journal-title":"Cardiovasc Drugs Ther"},{"key":"6496_CR7","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3324\/HAEMATOL.2024.285805","volume":"110","author":"MA Sobas","year":"2025","unstructured":"Sobas MA, Turki AT, Ramiro AV, Hern\u00e1ndez-S\u00e1nchez A, Martinez Elicegui J, Gonz\u00e1lez T, Melchor RA, Ab\u00e1igar M, Tur L, Dall\u2019olio D, Str\u00e4ng E, Tettero JM, Castellani G, Benner A, D\u00f6hner K, Thiede C, Metzeler KH, Haferlach T, Damm F, Ayala R, Mart\u00ednez-L\u00f3pez J, Mills KI, Sierra J, Lehmann S, Della Porta MG, Mayer J, Reinhardt D, Medina RV, Schulze-Rath R, Barbus M, Mar\u00eda Hern\u00e1ndez-Rivas J, Huntly BJP, Ossenkoppele G, D\u00f6hner H, Bullinger L, Bullinger L (2025) Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY alliance. Haematologica 110:1126\u20131140. https:\/\/doi.org\/10.3324\/HAEMATOL.2024.285805","journal-title":"Haematologica"},{"key":"6496_CR8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMOA2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, D\u00f6hner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, H\u00e1jek R, Porkka K, Ill\u00e9s \u00c1, Lavie D, Lemoli RM, Yamamoto K, Yoon S-S, Jang J-H, Yeh S-P, Turgut M, Hong W-J, Zhou Y, Potluri J, Pratz KW (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617\u2013629. https:\/\/doi.org\/10.1056\/NEJMOA2012971","journal-title":"N Engl J Med"},{"key":"6496_CR9","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1182\/BLOODADVANCES.2019001267","volume":"4","author":"CA Lachowiez","year":"2020","unstructured":"Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, Di Nardo CD (2020) Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv 4:1311\u20131320. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2019001267","journal-title":"Blood Adv"},{"key":"6496_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/BLOOD-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A (2019) Venetoclax combined with decitabine or Azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133:7\u201317. https:\/\/doi.org\/10.1182\/BLOOD-2018-08-868752","journal-title":"Blood"},{"key":"6496_CR11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/BJH.18887","volume":"202","author":"C Sartor","year":"2023","unstructured":"Sartor C, Brunetti L, Audisio E, Cignetti A, Zannoni L, Cristiano G, Nanni J, Ciruolo R, Zingarelli F, Ottaviani E, Patuelli A, Bandini L, Forte D, Sciabolacci S, Cardinali V, Papayannidis C, Cavo M, Martelli MP, Curti A (2023) A venetoclax and Azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure. Br J Haematol 202:599\u2013607. https:\/\/doi.org\/10.1111\/BJH.18887","journal-title":"Br J Haematol"},{"key":"6496_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/BLOODADVANCES.2024013086","volume":"9","author":"JM Unglaub","year":"2025","unstructured":"Unglaub JM, Schlenk RF, Middeke JM, Krause SW, Kraus S, Einsele H, Kramer M, Zukunft S, Kauer J, Renders S, Katelari E, Schliemann C, Pabst C, Luft T, Dreger P, R\u00f6llig C, Bornh\u00e4user M, M\u00fcller-Tidow C, Sauer T (2025) Venetoclax-based salvage therapy as a Bridge to transplant is feasible and effective in patients with relapsed\/refractory AML. Blood Adv 9:375\u2013385. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2024013086","journal-title":"Blood Adv"},{"key":"6496_CR13","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/BLOODADVANCES.2020003734","volume":"5","author":"M Stahl","year":"2021","unstructured":"Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King AC, Daniyan AF, Famulare C, Cuello BM, Horvat TZ, Abdel-Wahab O, Levine RL, Viny AD, Stein EM, Cai SF, Roshal M, Tallman MS, Goldberg AD (2021) Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML. Blood Adv 5:1552\u20131564. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2020003734","journal-title":"Blood Adv"},{"key":"6496_CR14","unstructured":"Chow S-C, Wang H, Shao J (2008) Sample size calculations in clinical research, 2nd edn. Chapman and Hall\/CRC"},{"key":"6496_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1200\/JCO.19.01406","volume":"38","author":"RF Schlenk","year":"2020","unstructured":"Schlenk RF, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik VI, Leis C, Fiedler W, Kindler T, Schroeder T, Mayer K, L\u00fcbbert M, Wattad M, G\u00f6tze K, Horst HA, Koller E, Wulf G, Schleicher J, Bentz M, Greil R, Hertenstein B, Krauter J, Martens U, Nachbaur D, Samra MA, Girschikofsky M, Basara N, Benner A, Thol F, Heuser M, Ganser A, D\u00f6hner K, D\u00f6hner H (2020) Gemtuzumab Ozogamicin in NPM1-Mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09\u201309 phase III study. J Clin Oncol 38:623\u2013632. https:\/\/doi.org\/10.1200\/JCO.19.01406","journal-title":"J Clin Oncol"},{"key":"6496_CR16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/BLOOD.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R, Pomilio G, Ivey A, Salmon JM, Glytsou C, Fleming SA, Zhang Q, Ma H, Patel KP, Kornblau SM, Xu Z, Chua CC, Chen X, Blombery P, Flensburg C, Cummings N, Aifantis I, Kantarjian H, Huang DCS, Roberts AW, Majewski IJ, Konopleva M, Wei AH (2020) Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135:791\u2013803. https:\/\/doi.org\/10.1182\/BLOOD.2019003988","journal-title":"Blood"},{"key":"6496_CR17","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMOA1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou W-C, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon S-S, Lee J-H, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ (2019) Gilteritinib or chemotherapy for relapsed or refractory FLT3-Mutated AML. N Engl J Med 381:1728\u20131740. https:\/\/doi.org\/10.1056\/NEJMOA1902688","journal-title":"N Engl J Med"},{"key":"6496_CR18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMOA1614359\/SUPPL_FILE\/NEJMOA1614359_DISCLOSURES.PDF","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, D\u00f6hner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, D\u00f6hner H (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377:454\u2013464. https:\/\/doi.org\/10.1056\/NEJMOA1614359\/SUPPL_FILE\/NEJMOA1614359_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"key":"6496_CR19","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1182\/BLOODADVANCES.2024012858","volume":"8","author":"JP Bewersdorf","year":"2024","unstructured":"Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Bystrom R, Lindsley RC, Chen EC, Ramos Perez JM, Stein AS, Pullarkat VA, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garciaz S, Ball BJ, Stahl M (2024) Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML. Blood Adv 8:4845\u20134855. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2024012858","journal-title":"Blood Adv"},{"key":"6496_CR20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/BLOOD.2023021579","volume":"143","author":"J Othman","year":"2024","unstructured":"Othman J, Tiong IS, O\u2019Nions J, Dennis M, Mokretar K, Ivey A, Austin M, Latif AL, Amer M, Chan WY, Crawley C, Crolla F, Cross J, Dang R, Elliot J, Fong CY, Galli S, Gallipoli P, Hogan F, Kalkur P, Khan A, Krishnamurthy P, Laurie J, Loo S, Marshall S, Mehta P, Murthy V, Nagumantry S, Pillai S, Potter N, Sellar R, Taylor T, Zhao R, Russell NH, Wei AH, Dillon R (2024) Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy. Blood 143:336\u2013341. https:\/\/doi.org\/10.1182\/BLOOD.2023021579","journal-title":"Blood"},{"key":"6496_CR21","doi-asserted-by":"publisher","unstructured":"Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM (2023) The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature 2023 615:7954. 615:920\u2013924. https:\/\/doi.org\/10.1038\/s41586-023-05812-3","DOI":"10.1038\/s41586-023-05812-3"},{"key":"6496_CR22","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1182\/BLOOD-2024-207106","volume":"144","author":"E Searle","year":"2024","unstructured":"Searle E, Recher C, Abdul-Hay M, Abedin S, Aldoss I, Pierola AA, Alonso-Dominguez JM, Chevallier P, Cost C, Daskalakis N, Dillon R, Dunavin N, Esteve J, Fathi AT, Fedele PL, Ferrante L, Gaj S, Guttke C, Gyan E, Hiebert B, Jabbour E, Kantarjian HM, Kwon MC, Kumar AJ, Ng TF, Packman K, Philippar U, Pigneux A, Salamero O, Sanga M, Nagaraja Shastri P, Stone RM, Tan P, Tucker T, Vyas P, Garciaz S (2024) Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed\/refractory acute leukemia patients with KMT2A and NPM1 alterations. Blood 144:212\u2013212. https:\/\/doi.org\/10.1182\/BLOOD-2024-207106","journal-title":"Blood"},{"key":"6496_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1182\/BLOOD-2023-185437","volume":"142","author":"S Garciaz","year":"2023","unstructured":"Garciaz S, Bertoli S, Sallman DA, Decroocq J, Dumas P-Y, Belhabri A, Orvain C, Aspas Requena G, Simand C, Laribi K, Carr\u00e9 M, Santagostino A, Gabellier L, Hospital MA, Mineur A, Pigneux A, Vey N, R\u00e9cher C (2023) Acute myeloid leukemia patients who stopped venetoclax or\/and Azacytidine for other reasons than progression have A prolonged treatment free remission and overall survival. A Filo study. Blood 142:161\u2013161. https:\/\/doi.org\/10.1182\/BLOOD-2023-185437","journal-title":"Blood"},{"key":"6496_CR24","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1182\/BLOODADVANCES.2022007083","volume":"6","author":"CC Chua","year":"2022","unstructured":"Chua CC, Hammond D, Kent A, Tiong IS, Konopleva MY, Pollyea DA, DiNardo CD, Wei AH (2022) Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. Blood Adv 6:3879\u20133883. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2022007083","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06496-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06496-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06496-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T16:03:50Z","timestamp":1754669030000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06496-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6496"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06496-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"20 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study (NCT05904106) is conducted in accordance with the Declaration of Helsinki and approved by the institutional bioethics review committee of the Technische Universit\u00e4t (TU) Dresden (EK13012023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"LK: Travel grants: AbbVie Inc., Beigene, Jazz Pharmaceuticals, Johnson & Johnson. LR: Travel grants: BeiGene, Inc., AbbVie Inc., Jazz Pharmaceuticals, Johnson & Johnson, Neovii Pharmaceuticals; Consultancy und Honoraria: Actitrexx GmbH, AbbVie Inc.; Research Funding: AbbVie Inc. CR: Consultancy und Honoraria: AbbVie Inc., Amgen, Astellas, Bristol-Meyer-Squibb, Daiichi Sankyo, Jazz Pharmaceuticals, J&J, Novartis, Otsuka, Pfizer, Roche, Servier; Research Funding: AbbVie Inc., Astellas, Novartis, Pfizer. CS: Honoraria\/Advisory Boards: AbbVie Inc., Astellas, AstraZeneca, Bristol-Meyer-Squibb, Laboratories Delbert, Jazz Pharmaceuticals, Novartis, Otsuka, Pfizer, Roche; Research support (institutional): Jazz Pharmaceuticals; Travel grants: AbbVie Inc., Bristol-Meyer-Squibb, Jazz Pharmaceuticals, Pfizer. LF: Consultancy und Honoraria: AbbVie Inc.; Research Funding: AbbVie Inc. RSB: Honoraria: AbbVie Inc., Amgen, Astra Zeneca, Beigene, Bristol-Meyer-Squibb, Celgene, Eusa Pharma, IPSEN, Merck, MSD, Novartis, Pfizer, Roche; Membership on an entity\u2019s Board of Directors or advisory committees: AbbVie Inc., Beigene, MSD, Novartis, Roche.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}